Stockpolly
Search
Delisting risk
ATYR · NASDAQ · Biotechnology

aTyr Pharma (ATYR)

Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.

$0.5000
Pre-market+0.00 (+0.20%)
At close$0.4990(+4.72%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue10000120022000
Gross profit−10000−1200−22000
1216171718416205151111
Research & development1013131415121215221177
234334455444
Selling & marketing−100000000000
General & administrative334334455444
Other expenses00000−1200−22000
Operating income−13−16−17−17−18−16−16−20−27−15−11−11
111111111111
Other non-operating income0−1−1−1−1−1−1−1−1−1−1−1
Income before tax−11−15−15−16−17−15−15−20−26−14−11−10
Net income from continuing operations−11−15−15−16−17−15−15−20−26−14−11−10
Net income−11−15−15−16−17−15−15−20−26−14−11−10
EPS, basic−$0.20−$0.25−$0.23−$0.23−$0.23−$0.18−$0.17−$0.22−$0.26−$0.14−$0.11−$0.11
EPS, diluted−$0.20−$0.25−$0.23−$0.23−$0.23−$0.18−$0.17−$0.22−$0.26−$0.14−$0.11−$0.11
Weighted average shares, basic585966727683869097989898
Weighted average shares, diluted585966727683869097989898
EBITDA−12−14−15−16−17−15−14−19−26−14−10−9
Depreciation & amortization101000000001
EBIT−13−15−15−16−17−15−15−20−26−14−11−10